Abstract
Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary manifestation that has been associated with various diseases. It is a medical emergency that requires prompt diagnosis and aggressive treatment. The clinical manifestations consist of hemoptysis, hypoxia, a drop in the hemoglobin level and new pulmonary infiltrates on chest X-ray. Infrequently, Systemic lupus erythematosus (SLE) and Antiphospholipid syndrome (APS) could be complicated by this severe pulmonary manifestation. The most common histologic lesion in SLE and Antiphospholipid Syndrome is pulmonary capillaritis. Corticosteroids with or without immunosuppressive agents such as cyclophosphamide are the mainstay of the therapy. Plasmapheresis, intravenous immunoglobulin or the newer biologic agents would be considered if there is a persistent lack of clinical response.
Keywords: Systemic lupus erythematosus, diffuse alveolar hemorrhage, antiphospholipid syndrome, pulmonary hemorrhage
Current Respiratory Medicine Reviews
Title: Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Volume: 5 Issue: 2
Author(s): Javier A. Cavallasca, Maria del Rosario Maliandi, Diego H. Goffredo and Gustavo G. Nasswetter
Affiliation:
Keywords: Systemic lupus erythematosus, diffuse alveolar hemorrhage, antiphospholipid syndrome, pulmonary hemorrhage
Abstract: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary manifestation that has been associated with various diseases. It is a medical emergency that requires prompt diagnosis and aggressive treatment. The clinical manifestations consist of hemoptysis, hypoxia, a drop in the hemoglobin level and new pulmonary infiltrates on chest X-ray. Infrequently, Systemic lupus erythematosus (SLE) and Antiphospholipid syndrome (APS) could be complicated by this severe pulmonary manifestation. The most common histologic lesion in SLE and Antiphospholipid Syndrome is pulmonary capillaritis. Corticosteroids with or without immunosuppressive agents such as cyclophosphamide are the mainstay of the therapy. Plasmapheresis, intravenous immunoglobulin or the newer biologic agents would be considered if there is a persistent lack of clinical response.
Export Options
About this article
Cite this article as:
Cavallasca A. Javier, Maliandi del Rosario Maria, Goffredo H. Diego and Nasswetter G. Gustavo, Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome, Current Respiratory Medicine Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339809788189987
DOI https://dx.doi.org/10.2174/157339809788189987 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Triple Antithrombotic Therapy vs. Double Antithrombotic Therapy: One Scenario, 8 Questions, Many Conclusions
Current Cardiology Reviews Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges
Current Drug Metabolism Heterogeneity of Synthetic Factor Xa Inhibitors
Current Pharmaceutical Design PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Lung Ultrasound in the Critically Ill Neonate
Current Pediatric Reviews Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Clopidogrel in Secondary Ischemic Stroke Prevention
Recent Patents on Cardiovascular Drug Discovery The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology Effect of Low Molecular Weight Heparins and Fondaparinux Upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3
Current Vascular Pharmacology Behavioral Effects of 2,3-Dihydro- and Oxoisoaporphine Derivatives in Post Stroke-Depressive Like Behavior in Male Balb/c Mice
Current Topics in Medicinal Chemistry Protrhombotic Effects of Contraceptives
Current Pharmaceutical Design